| abstract |
Two active agents selected from a pharmaceutically acceptable carrier and a compound having symptomatic and / or neuroprotective effects on Parkinson's disease patients in a molar ratio of 1: 1 to 1: 100. A pharmaceutical composition for the treatment of Parkinson's disease comprising a fixed dosage combination comprising is provided. This pharmaceutical composition is formulated for immediate release, sustained release, or both immediate and sustained release. |